InvestSMART

Anteris Technologies Ltd (ASX:AVR)

ALERT: Price-sensitive ASX Announcement for AVR
Current share price for AVR : $11.290 2.38 (26.71%)+
Announcement
Release
23 Jan 2026 9:29AM
Price at Release
$8.910
Full Release
download
Summary
Anteris Technologies Ltd, operating under the NASDAQ and ASX ticker AVR, announced the closing of a $US 230 million public offering of common stock, alongside a private placement with Medtronic. The public offering involved 40,000,000 shares at $US 5.75 per share, while the private placement consisted of 15,652,173 shares at the same price. The total gross proceeds from these initiatives amounted to approximately $US 320 million. Anteris plans to utilize these funds to further its clinical strategy, including conducting the global pivotal trial for its DurAVR® Transcatheter Heart Valve (THV) designed for aortic stenosis treatment, expand manufacturing capabilities, and continue research and development efforts. The company's lead product, the DurAVR® THV, leverages biomimetic design and ADAPT® tissue technology, which has been FDA-cleared and used in over 55,000 patients worldwide.
Key Points
  • Anteris Technologies closes $US 230 million public offering.
  • Offering includes 40,000,000 shares at $US 5.75 each.
  • Private placement with Medtronic involves 15,652,173 shares.
  • Gross proceeds from activities total approximately $US 320 million.
  • Funds to support DurAVR® THV global trial and manufacturing expansion.
  • DurAVR® THV uses FDA-cleared ADAPT® tissue technology.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.